CA2678693A1 - Method and test kit for determining the amounts of target sequences and nucleotide variations therein - Google Patents

Method and test kit for determining the amounts of target sequences and nucleotide variations therein Download PDF

Info

Publication number: CA2678693A1
Authority: CA; Canada
Prior art keywords: target; targets; probes; detector; probe
Prior art date: 2007-02-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002678693A

Other languages

English (en)

French (fr)

Inventor

Hans Soederlund

Jari Rautio

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Valtion Teknillinen Tutkimuskeskus

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-21

Filing date

2008-02-20

Publication date

2008-08-28

2008-02-20 Application filed by Individual filed Critical Individual

2008-08-28 Publication of CA2678693A1 publication Critical patent/CA2678693A1/en

Status Abandoned legal-status Critical Current

Links

239000002773 nucleotide Substances 0.000 title claims abstract description 198
125000003729 nucleotide group Chemical group 0.000 title claims abstract description 198
238000000034 method Methods 0.000 title claims abstract description 124
238000012360 testing method Methods 0.000 title claims abstract description 29
239000000523 sample Substances 0.000 claims abstract description 408
239000007787 solid Substances 0.000 claims abstract description 46
108091033319 polynucleotide Proteins 0.000 claims abstract description 44
102000040430 polynucleotide Human genes 0.000 claims abstract description 44
239000002157 polynucleotide Substances 0.000 claims abstract description 44
102000004190 Enzymes Human genes 0.000 claims abstract description 27
108090000790 Enzymes Proteins 0.000 claims abstract description 27
230000000295 complement effect Effects 0.000 claims abstract description 27
239000003153 chemical reaction reagent Substances 0.000 claims abstract description 13
238000009396 hybridization Methods 0.000 claims description 73
238000006243 chemical reaction Methods 0.000 claims description 47
239000000243 solution Substances 0.000 claims description 37
230000014509 gene expression Effects 0.000 claims description 36
108020004414 DNA Proteins 0.000 claims description 34
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 22
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 15
239000012488 sample solution Substances 0.000 claims description 15
102100034343 Integrase Human genes 0.000 claims description 14
238000005406 washing Methods 0.000 claims description 14
238000000926 separation method Methods 0.000 claims description 13
239000007853 buffer solution Substances 0.000 claims description 11
239000005546 dideoxynucleotide Substances 0.000 claims description 11
229960002685 biotin Drugs 0.000 claims description 10
235000020958 biotin Nutrition 0.000 claims description 10
239000011616 biotin Substances 0.000 claims description 10
239000000872 buffer Substances 0.000 claims description 10
238000005251 capillar electrophoresis Methods 0.000 claims description 10
108700028369 Alleles Proteins 0.000 claims description 9
238000004458 analytical method Methods 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
108091034117 Oligonucleotide Proteins 0.000 claims description 7
108090001008 Avidin Proteins 0.000 claims description 6
108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 6
239000000463 material Substances 0.000 claims description 6
102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
239000012634 fragment Substances 0.000 claims description 5
108010090804 Streptavidin Proteins 0.000 claims description 3
238000006911 enzymatic reaction Methods 0.000 claims description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
238000004020 luminiscence type Methods 0.000 claims description 3
238000009877 rendering Methods 0.000 claims description 3
108090001090 Lectins Proteins 0.000 claims description 2
102000004856 Lectins Human genes 0.000 claims description 2
238000010521 absorption reaction Methods 0.000 claims description 2
238000007865 diluting Methods 0.000 claims description 2
238000001502 gel electrophoresis Methods 0.000 claims description 2
238000003205 genotyping method Methods 0.000 claims description 2
239000002523 lectin Substances 0.000 claims description 2
239000003446 ligand Substances 0.000 claims description 2
229910052751 metal Inorganic materials 0.000 claims description 2
239000002184 metal Substances 0.000 claims description 2
239000013522 chelant Substances 0.000 claims 1
150000004676 glycans Chemical class 0.000 claims 1
108020004999 messenger RNA Proteins 0.000 description 30
239000000700 radioactive tracer Substances 0.000 description 26
238000003149 assay kit Methods 0.000 description 24
210000004027 cell Anatomy 0.000 description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 22
201000010099 disease Diseases 0.000 description 19
201000003883 Cystic fibrosis Diseases 0.000 description 17
230000035772 mutation Effects 0.000 description 17
238000001514 detection method Methods 0.000 description 15
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
239000000126 substance Substances 0.000 description 12
241000282414 Homo sapiens Species 0.000 description 11
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 11
239000006166 lysate Substances 0.000 description 11
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 9
239000000975 dye Substances 0.000 description 9
238000010369 molecular cloning Methods 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
238000011282 treatment Methods 0.000 description 9
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
238000010828 elution Methods 0.000 description 8
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 8
150000003839 salts Chemical class 0.000 description 8
-1 Cy5 Chemical compound 0.000 description 7
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 7
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
235000019333 sodium laurylsulphate Nutrition 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
108020004705 Codon Proteins 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
108020005187 Oligonucleotide Probes Proteins 0.000 description 6
239000011324 bead Substances 0.000 description 6
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 6
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000036541 health Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
238000004949 mass spectrometry Methods 0.000 description 6
238000002493 microarray Methods 0.000 description 6
239000002751 oligonucleotide probe Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
101150104391 traT gene Proteins 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
238000011277 treatment modality Methods 0.000 description 6
206010009944 Colon cancer Diseases 0.000 description 5
ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 5
208000029742 colonic neoplasm Diseases 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
238000002372 labelling Methods 0.000 description 5
150000007523 nucleic acids Chemical group 0.000 description 5
239000002245 particle Substances 0.000 description 5
238000011160 research Methods 0.000 description 5
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 4
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
239000011325 microbead Substances 0.000 description 4
239000011859 microparticle Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
101150029409 CFTR gene Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
239000003298 DNA probe Substances 0.000 description 3
101100425960 Escherichia coli traT gene Proteins 0.000 description 3
208000026350 Inborn Genetic disease Diseases 0.000 description 3
239000002585 base Substances 0.000 description 3
URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
238000000265 homogenisation Methods 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
239000013641 positive control Substances 0.000 description 3
238000004393 prognosis Methods 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
238000013519 translation Methods 0.000 description 3
VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
SSJZAXOTLCJNLF-UHFFFAOYSA-M 2,3-bis(4-methylphenyl)tetrazol-2-ium-5-carbonitrile;chloride Chemical compound [Cl-].C1=CC(C)=CC=C1N1[N+](C=2C=CC(C)=CC=2)=NC(C#N)=N1 SSJZAXOTLCJNLF-UHFFFAOYSA-M 0.000 description 2
QEQDLKUMPUDNPG-UHFFFAOYSA-N 2-(7-amino-4-methyl-2-oxochromen-3-yl)acetic acid Chemical compound C1=C(N)C=CC2=C1OC(=O)C(CC(O)=O)=C2C QEQDLKUMPUDNPG-UHFFFAOYSA-N 0.000 description 2
YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 2
YJCCSLGGODRWKK-NSCUHMNNSA-N 4-Acetamido-4'-isothiocyanostilbene-2,2'-disulphonic acid Chemical compound OS(=O)(=O)C1=CC(NC(=O)C)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YJCCSLGGODRWKK-NSCUHMNNSA-N 0.000 description 2
IGHBXJSNZCFXNK-UHFFFAOYSA-N 4-chloro-7-nitrobenzofurazan Chemical compound [O-][N+](=O)C1=CC=C(Cl)C2=NON=C12 IGHBXJSNZCFXNK-UHFFFAOYSA-N 0.000 description 2
BRLRJZRHRJEWJY-VCOUNFBDSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[3-[3-(4-azido-2-nitroanilino)propyl-methylamino]propyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCN(C)CCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O BRLRJZRHRJEWJY-VCOUNFBDSA-N 0.000 description 2
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
RDFLLVCQYHQOBU-GPGGJFNDSA-O Cyanin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO)O1)c1c(-c2cc(O)c(O)cc2)[o+]c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)cc(O)c2)c1 RDFLLVCQYHQOBU-GPGGJFNDSA-O 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 2
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
208000028782 Hereditary disease Diseases 0.000 description 2
101000795018 Homo sapiens Putative trypsin-6 Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
208000024556 Mendelian disease Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
102100029629 Putative trypsin-6 Human genes 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
VCORFLZFSPUNDN-UAGCYRGNSA-N [(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-[[(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(6-aminopurin-9-yl)-2-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@H](O[C@@H]1COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(O)=O)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C(N=CN=C2N)=C2N=C1 VCORFLZFSPUNDN-UAGCYRGNSA-N 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
108010004469 allophycocyanin Proteins 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000004590 computer program Methods 0.000 description 2
RDFLLVCQYHQOBU-ZOTFFYTFSA-O cyanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RDFLLVCQYHQOBU-ZOTFFYTFSA-O 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000007614 genetic variation Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
WMPJPAMWRAOQSU-UHFFFAOYSA-N naphthalene-1,2-dicarbaldehyde Chemical compound C1=CC=CC2=C(C=O)C(C=O)=CC=C21 WMPJPAMWRAOQSU-UHFFFAOYSA-N 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
108060006184 phycobiliprotein Proteins 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
230000008263 repair mechanism Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
239000003161 ribonuclease inhibitor Substances 0.000 description 2
238000000527 sonication Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
238000012085 transcriptional profiling Methods 0.000 description 2
239000004474 valine Substances 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
QSVQMVRTWNDRDT-UHFFFAOYSA-N (1-methylindol-3-yl) acetate Chemical compound C1=CC=C2C(OC(=O)C)=CN(C)C2=C1 QSVQMVRTWNDRDT-UHFFFAOYSA-N 0.000 description 1
OOKWHTKWDDXSKE-UHFFFAOYSA-N (1-methylindol-3-yl) tetradecanoate Chemical compound C1=CC=C2C(OC(=O)CCCCCCCCCCCCC)=CN(C)C2=C1 OOKWHTKWDDXSKE-UHFFFAOYSA-N 0.000 description 1
CXYYHBMOVJJZTD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3',6'-bis(dimethylamino)-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound C=1C(N(C)C)=CC=C2C=1OC1=CC(N(C)C)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2C(=O)ON1C(=O)CCC1=O CXYYHBMOVJJZTD-UHFFFAOYSA-N 0.000 description 1
NXIABCNYUKDBQI-UHFFFAOYSA-N (3-oxo-6'-propanoyloxyspiro[2-benzofuran-1,9'-xanthene]-3'-yl) propanoate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(=O)CC)C=C1OC1=CC(OC(=O)CC)=CC=C21 NXIABCNYUKDBQI-UHFFFAOYSA-N 0.000 description 1
BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
WZEWYQWWSCVHCP-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) octanoate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCCCCCC)=CC=C21 WZEWYQWWSCVHCP-UHFFFAOYSA-N 0.000 description 1
CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
MYTRGBGGRICZGN-UHFFFAOYSA-N (6'-dodecanoyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) dodecanoate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(=O)CCCCCCCCCCC)C=C1OC1=CC(OC(=O)CCCCCCCCCCC)=CC=C21 MYTRGBGGRICZGN-UHFFFAOYSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
HZSKRKPZUQECIE-UHFFFAOYSA-N 2-ethoxy-n-[4-[(5-methyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)COCC)=CC=C1S(=O)(=O)NC1=NOC(C)=C1 HZSKRKPZUQECIE-UHFFFAOYSA-N 0.000 description 1
BNBQQYFXBLBYJK-UHFFFAOYSA-N 2-pyridin-2-yl-1,3-oxazole Chemical compound C1=COC(C=2N=CC=CC=2)=N1 BNBQQYFXBLBYJK-UHFFFAOYSA-N 0.000 description 1
VUSZJWOKNYZNPK-UHFFFAOYSA-N 3',6'-diacetyloxy-2',4',5',7'-tetrabromo-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carboxylic acid;3',6'-diacetyloxy-2',4',5',7'-tetrabromo-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid Chemical compound O1C(=O)C2=CC(C(O)=O)=CC=C2C21C1=CC(Br)=C(OC(C)=O)C(Br)=C1OC1=C(Br)C(OC(=O)C)=C(Br)C=C21.O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(Br)=C(OC(C)=O)C(Br)=C1OC1=C(Br)C(OC(=O)C)=C(Br)C=C21 VUSZJWOKNYZNPK-UHFFFAOYSA-N 0.000 description 1
WPUZGNPQMIWOHE-UHFFFAOYSA-N 3',6'-diacetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid Chemical compound O1C(=O)C2=CC(C(O)=O)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 WPUZGNPQMIWOHE-UHFFFAOYSA-N 0.000 description 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
QWBZNOKUBXSLRE-UHFFFAOYSA-N 3-O-methylfluorescein 6-phosphate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OP(O)(O)=O)C=C1OC1=CC(OC)=CC=C21 QWBZNOKUBXSLRE-UHFFFAOYSA-N 0.000 description 1
QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical class C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
FUYLLJCBCKRIAL-UHFFFAOYSA-N 4-methylumbelliferone sulfate Chemical compound C1=C(OS(O)(=O)=O)C=CC2=C1OC(=O)C=C2C FUYLLJCBCKRIAL-UHFFFAOYSA-N 0.000 description 1
GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
AVEQMYZAGPYSNN-UHFFFAOYSA-N 6,8-difluoro-7-hydroxychromen-2-one Chemical compound C1=CC(=O)OC2=C(F)C(O)=C(F)C=C21 AVEQMYZAGPYSNN-UHFFFAOYSA-N 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
241001504639 Alcedo atthis Species 0.000 description 1
239000012099 Alexa Fluor family Substances 0.000 description 1
108091029845 Aminoallyl nucleotide Proteins 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
VLKSJYFGXZQSDX-UHFFFAOYSA-N BrC1=CC=C2NC(OP(O)(=O)O)=CC2=C1Cl Chemical compound BrC1=CC=C2NC(OP(O)(=O)O)=CC2=C1Cl VLKSJYFGXZQSDX-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
102000020897 Formins Human genes 0.000 description 1
108091022623 Formins Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000035467 Pancreatic insufficiency Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
201000011252 Phenylketonuria Diseases 0.000 description 1
108010026501 R-phycocyanin II Proteins 0.000 description 1
238000013381 RNA quantification Methods 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
208000002903 Thalassemia Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
239000003513 alkali Substances 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
239000012491 analyte Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000000712 assembly Effects 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
WWAABJGNHFGXSJ-UHFFFAOYSA-N chlorophenol red Chemical compound C1=C(Cl)C(O)=CC=C1C1(C=2C=C(Cl)C(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 WWAABJGNHFGXSJ-UHFFFAOYSA-N 0.000 description 1
229930002875 chlorophyll Natural products 0.000 description 1
235000019804 chlorophyll Nutrition 0.000 description 1
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
150000004775 coumarins Chemical class 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003297 denaturating effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940098008 erythrocin Drugs 0.000 description 1
IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 1
HBNYJWAFDZLWRS-UHFFFAOYSA-N ethyl isothiocyanate Chemical compound CCN=C=S HBNYJWAFDZLWRS-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
229940043045 fluorescein dilaurate Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000002761 liquid phase assay Methods 0.000 description 1
DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
UATCLPJEZJKNHE-UHFFFAOYSA-N n-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)-2-iodoacetamide Chemical compound O1C(=O)C2=CC(NC(=O)CI)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 UATCLPJEZJKNHE-UHFFFAOYSA-N 0.000 description 1
HENCSKZMSUJDLA-UHFFFAOYSA-N n-[3',6'-bis(dimethylamino)-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl]-2-iodoacetamide Chemical compound O1C(=O)C2=CC(NC(=O)CI)=CC=C2C21C1=CC=C(N(C)C)C=C1OC1=CC(N(C)C)=CC=C21 HENCSKZMSUJDLA-UHFFFAOYSA-N 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000000243 photosynthetic effect Effects 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
YTFLOMYZTLUWHX-UHFFFAOYSA-N pyrene-1-sulfonyl chloride Chemical compound C1=C2C(S(=O)(=O)Cl)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 YTFLOMYZTLUWHX-UHFFFAOYSA-N 0.000 description 1
150000003220 pyrenes Chemical class 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
229910052761 rare earth metal Inorganic materials 0.000 description 1
150000002910 rare earth metals Chemical class 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
102000037983 regulatory factors Human genes 0.000 description 1
108091008025 regulatory factors Proteins 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002336 sorption--desorption measurement Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000758 substrate Substances 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
239000002699 waste material Substances 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA002678693A 2007-02-21 2008-02-20 Method and test kit for determining the amounts of target sequences and nucleotide variations therein Abandoned CA2678693A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FI20075124		2007-02-21
FI20075124A FI20075124A0 (fi)	2007-02-21	2007-02-21	Menetelmä ja testikitti nukleotidivariaatioiden toteamiseksi
PCT/FI2008/050074 WO2008102057A1 (en)	2007-02-21	2008-02-20	Method and test kit for determining the amounts of target sequences and nucleotide variations therein

Publications (1)

Publication Number	Publication Date
CA2678693A1 true CA2678693A1 (en)	2008-08-28

Family

ID=37832273

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002678693A Abandoned CA2678693A1 (en)	2007-02-21	2008-02-20	Method and test kit for determining the amounts of target sequences and nucleotide variations therein

Country Status (6)

Country	Link
EP (1)	EP2126122A4 (ja)
JP (1)	JP2010518846A (ja)
AU (1)	AU2008217678B9 (ja)
CA (1)	CA2678693A1 (ja)
FI (1)	FI20075124A0 (ja)
WO (1)	WO2008102057A1 (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9029085B2 (en)	2007-03-07	2015-05-12	President And Fellows Of Harvard College	Assays and other reactions involving droplets
JP5738597B2 (ja)	2007-12-21	2015-06-24	プレジデントアンドフェローズオブハーバードカレッジ	核酸の配列決定のためのシステムおよび方法
WO2010033200A2 (en)	2008-09-19	2010-03-25	President And Fellows Of Harvard College	Creation of libraries of droplets and related species
EP3150724A1 (en) *	2008-12-19	2017-04-05	President and Fellows of Harvard College	Particle-assisted nucleic acid sequencing
EP3842150A1 (en)	2009-10-27	2021-06-30	President and Fellows of Harvard College	Droplet creation techniques
MX352460B (es)	2011-01-11	2017-11-24	Seegene Inc	Detección de secuencias de ácido nucleico objetivo mediante ensayo de escisión y extensión del pto.
EP2691543B1 (en)	2011-03-29	2017-11-01	Seegene, Inc.	Detection of target nucleic acid sequence by pto cleavage and extension-dependent cleavage
US9850524B2 (en)	2011-05-04	2017-12-26	Seegene, Inc.	Detection of target nucleic acid sequences by PO cleavage and hybridization
KR20130101952A (ko)	2012-02-02	2013-09-16	주식회사 씨젠	Ｐｔｏ 절단과 연장-의존적 혼성화를 이용한 타겟 핵산서열의 검출
CA2864523C (en) *	2012-03-05	2019-02-05	Seegene, Inc.	Detection of nucleotide variation on target nucleic acid sequence by pto cleavage and extension assay
US10221442B2 (en)	2012-08-14	2019-03-05	10X Genomics, Inc.	Compositions and methods for sample processing
US9701998B2 (en)	2012-12-14	2017-07-11	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9951386B2 (en)	2014-06-26	2018-04-24	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10752949B2 (en)	2012-08-14	2020-08-25	10X Genomics, Inc.	Methods and systems for processing polynucleotides
WO2014028537A1 (en)	2012-08-14	2014-02-20	10X Technologies, Inc.	Microcapsule compositions and methods
US10273541B2 (en)	2012-08-14	2019-04-30	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US11591637B2 (en)	2012-08-14	2023-02-28	10X Genomics, Inc.	Compositions and methods for sample processing
US10400280B2 (en)	2012-08-14	2019-09-03	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9567631B2 (en)	2012-12-14	2017-02-14	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10323279B2 (en)	2012-08-14	2019-06-18	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10533221B2 (en)	2012-12-14	2020-01-14	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US9644204B2 (en)	2013-02-08	2017-05-09	10X Genomics, Inc.	Partitioning and processing of analytes and other species
ES2662825T3 (es)	2013-02-25	2018-04-09	Seegene, Inc.	Detección de variación de nucleótido en una secuencia de ácidos nucleicos diana
US10395758B2 (en)	2013-08-30	2019-08-27	10X Genomics, Inc.	Sequencing methods
EP3065712A4 (en)	2013-11-08	2017-06-21	President and Fellows of Harvard College	Microparticles, methods for their preparation and use
US9824068B2 (en)	2013-12-16	2017-11-21	10X Genomics, Inc.	Methods and apparatus for sorting data
DE202015009494U1 (de)	2014-04-10	2018-02-08	10X Genomics, Inc.	Fluidische Vorrichtungen und Systeme zur Einkapselung und Partitionierung von Reagenzien, und deren Anwendungen
MX2016016902A (es)	2014-06-26	2017-03-27	10X Genomics Inc	Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
WO2015200891A1 (en)	2014-06-26	2015-12-30	10X Technologies, Inc.	Processes and systems for nucleic acid sequence assembly
CN107002128A (zh)	2014-10-29	2017-08-01	10X 基因组学有限公司	用于靶核酸测序的方法和组合物
US9975122B2 (en)	2014-11-05	2018-05-22	10X Genomics, Inc.	Instrument systems for integrated sample processing
CA2972969A1 (en)	2015-01-12	2016-07-21	10X Genomics, Inc.	Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same
SG10201811337XA (en)	2015-01-13	2019-01-30	10X Genomics Inc	Systems and methods for visualizing structural variation and phasing information
WO2016130578A1 (en)	2015-02-09	2016-08-18	10X Genomics, Inc.	Systems and methods for determining structural variation and phasing using variant call data
US10525076B2 (en)	2015-02-20	2020-01-07	Rosalind Franklin University Of Medicine And Science	Antisense compounds targeting genes associated with cystic fibrosis
WO2016134021A1 (en)	2015-02-20	2016-08-25	Rosalind Franklin University Of Medicine And Science	Antisense compounds targeting genes associated with cystic fibrosis
WO2016138148A1 (en)	2015-02-24	2016-09-01	10X Genomics, Inc.	Methods for targeted nucleic acid sequence coverage
WO2016137973A1 (en)	2015-02-24	2016-09-01	10X Genomics Inc	Partition processing methods and systems
WO2017066231A1 (en)	2015-10-13	2017-04-20	President And Fellows Of Harvard College	Systems and methods for making and using gel microspheres
PT3882357T (pt)	2015-12-04	2022-09-05	10X Genomics Inc	Métodos e composições para análise de ácidos nucleicos
CN107024583B (zh) *	2016-01-29	2019-03-08	中国科学院苏州纳米技术与纳米仿生研究所	硫黄素t适配体、其筛选方法及应用
SG11201806757XA (en)	2016-02-11	2018-09-27	10X Genomics Inc	Systems, methods, and media for de novo assembly of whole genome sequence data
WO2017197338A1 (en)	2016-05-13	2017-11-16	10X Genomics, Inc.	Microfluidic systems and methods of use
US10011872B1 (en)	2016-12-22	2018-07-03	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10815525B2 (en)	2016-12-22	2020-10-27	10X Genomics, Inc.	Methods and systems for processing polynucleotides
US10550429B2 (en)	2016-12-22	2020-02-04	10X Genomics, Inc.	Methods and systems for processing polynucleotides
EP3545089B1 (en)	2017-01-30	2022-03-09	10X Genomics, Inc.	Methods and systems for droplet-based single cell barcoding
CN110870018A (zh)	2017-05-19	2020-03-06	10X基因组学有限公司	用于分析数据集的系统和方法
US10844372B2 (en)	2017-05-26	2020-11-24	10X Genomics, Inc.	Single cell analysis of transposase accessible chromatin
EP3445876B1 (en)	2017-05-26	2023-07-05	10X Genomics, Inc.	Single cell analysis of transposase accessible chromatin
EP3688188A4 (en)	2017-09-29	2021-06-16	Seegene, Inc.	DETECTION OF TARGET NUCLEAR ACID SEQUENCES BY PTO CLEAVAGE AND EXTENSION DEPENDENT NON-HYBRIDIZATION TEST
CN111051523B (zh)	2017-11-15	2024-03-19	10X基因组学有限公司	功能化凝胶珠
US10829815B2 (en)	2017-11-17	2020-11-10	10X Genomics, Inc.	Methods and systems for associating physical and genetic properties of biological particles
SG11202009889VA (en)	2018-04-06	2020-11-27	10X Genomics Inc	Systems and methods for quality control in single cell processing
AU2022256039A1 (en) *	2021-04-07	2023-11-02	University Of Massachusetts	Specific oligonucleotide-programmed readthrough of nonsense codons

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6013431A (en) *	1990-02-16	2000-01-11	Molecular Tool, Inc.	Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
WO1993004199A2 (en) *	1991-08-20	1993-03-04	Scientific Generics Limited	Methods of detecting or quantitating nucleic acids and of producing labelled immobilised nucleic acids
EP0672173B1 (en) *	1991-11-01	2002-08-28	Diatech Pty. Ltd.	Solid phase amplification process
WO1993020236A1 (en) *	1992-04-03	1993-10-14	Applied Biosystems, Inc.	Probe composition and method
EP0954612A2 (en) *	1996-11-06	1999-11-10	Sequenom, Inc.	Dna diagnostics based on mass spectrometry
WO1999028494A1 (en) *	1997-12-04	1999-06-10	Packard Bioscience Company	Methods of using probes for analyzing polynucleotide sequence
US6635419B1 (en) *	1999-02-16	2003-10-21	Applera Corporation	Polynucleotide sequencing method
JP2003527075A (ja) *	1999-03-25	2003-09-16	ハイセック，インコーポレーテッド	ハイブリダイゼーションによる配列分析のための、溶液ベースの方法
JP2001245698A (ja) *	1999-11-22	2001-09-11	Xiao Bing Wang	核酸検出法
FI115139B (fi) *	2001-01-10	2005-03-15	Valtion Teknillinen	Menetelmä ja testipakkaus solu- tai kudosnäytteissä olevien polynukleotidien määrässä tapahtuvien vaihteluiden kvantitatiiviseen ja/tai vertailevaan arvioimiseen
US20030077584A1 (en) *	2001-08-28	2003-04-24	Mark Kunkel	Methods and compositons for bi-directional polymorphism detection
JP3752466B2 (ja) *	2002-04-24	2006-03-08	株式会社日立製作所	遺伝子検査方法
JP4617403B2 (ja) *	2002-06-28	2011-01-26	プリメラディーエックスインコーポレイテッド	配列の相違を検出する方法
FI20021325A0 (fi) *	2002-07-05	2002-07-05	Valtion Teknillinen	Menetelmä ja reagenssipakkaus yksittäisten polynukleotidien määrän määrittämiseksi

2007
- 2007-02-21 FI FI20075124A patent/FI20075124A0/fi unknown
2008
- 2008-02-20 WO PCT/FI2008/050074 patent/WO2008102057A1/en active Application Filing
- 2008-02-20 EP EP08718527A patent/EP2126122A4/en not_active Withdrawn
- 2008-02-20 CA CA002678693A patent/CA2678693A1/en not_active Abandoned
- 2008-02-20 JP JP2009550736A patent/JP2010518846A/ja active Pending
- 2008-02-20 AU AU2008217678A patent/AU2008217678B9/en not_active Ceased

Also Published As

Publication number	Publication date
EP2126122A4 (en)	2010-11-10
WO2008102057A1 (en)	2008-08-28
WO2008102057A9 (en)	2008-10-09
FI20075124A0 (fi)	2007-02-21
JP2010518846A (ja)	2010-06-03
AU2008217678A1 (en)	2008-08-28
AU2008217678B2 (en)	2013-09-12
EP2126122A1 (en)	2009-12-02
AU2008217678B9 (en)	2013-10-03

Publication	Publication Date	Title
AU2008217678B2 (en)	2013-09-12	Method and test kit for determining the amounts of target sequences and nucleotide variations therein
US6180408B1 (en)	2001-01-30	Fluorescence polarization in nucleic acid analysis
CA2135607C (en)	2005-08-02	Chemical method for the analysis of dna sequences
US20050191636A1 (en)	2005-09-01	Detection of STRP, such as fragile X syndrome
US20120115140A1 (en)	2012-05-10	Molecular Diagnosis of Fragile X Syndrome Associated with FMR1 Gene
AU8162498A (en)	1999-01-04	Methods for the detection of multiple single nucleotide polymorphisms in a single reaction
US20090069190A1 (en)	2009-03-12	Methods for hla typing
US20110014621A1 (en)	2011-01-20	Detecting multinucleotide repeats
US20100086918A1 (en)	2010-04-08	Methods for High Sensitivity Detection of Genetic Polymorphisms
CN110914448A (zh)	2020-03-24	使用差异性标记的等位基因特异性探针分析混合样品的基于阵列的方法
US20090011944A1 (en)	2009-01-08	Method and test kit for detecting nucleotide variations
Ge et al.	2006	Detection of fetal DNA in maternal plasma by microarray coupled with emulsions PCR
EP1300473A1 (en)	2003-04-09	Method of detecting nucleotide polymorphism
Goto et al.	2002	Single-nucleotide polymorphism analysis by hybridization protection assay on solid support
JP2003522527A (ja)	2003-07-29	一塩基多型の検出
EP1392863B1 (en)	2008-04-23	Method for determining the presence of extension products
US20030124581A1 (en)	2003-07-03	Newborn screening for hemoglobinopathy by DNA microarray analysis
Li et al.	2006	Tag/anti-tag liquid-phase primer extension array: a flexible and versatile genotyping platform
JP2002209584A (ja)	2002-07-30	塩基多型を検出する方法
JP2001095574A (ja)	2001-04-10	塩基多型を検出する方法
JP2003135069A (ja)	2003-05-13	塩基多型の同定方法
JP2005027519A (ja)	2005-02-03	ヒトチトクロームｐ４５０２ａ６遺伝子多型の簡易検出方法および検出用試薬
JP2002034599A (ja)	2002-02-05	１塩基多型を検出する方法

Legal Events

Date	Code	Title	Description
2013-02-08	EEER	Examination request	Effective date: 20130130
2015-04-19	FZDE	Discontinued	Effective date: 20150220